DNA site-specific N3-adenine methylation targeted to estrogen receptor-positive cells.
Rigel J Kishton, Sean E Miller, Heather Perry, Tera Lynch, Mayur Patel, Vinayak K Gore, Giridhar R Akkaraju, Sridhar Varadarajan
Index: Bioorg. Med. Chem. 19 , 5093-102, (2011)
Full Text: HTML
Abstract
A compound that can target cells expressing the estrogen receptor (ER), and produce predominantly 3-MeA adducts in those cells has been designed and synthesized. This compound produces mainly the 3-MeA adduct upon reaction with calf thymus DNA, and binds to the ER with a relative binding affinity of 51% (estradiol = 100%). The compound is toxic to ER-expressing MCF-7 breast cancer cells, and pre-treatment with the ER antagonist fulvestrant abrogates the toxicity. Pre-treatment of MCF-7 cells with netropsin, which inhibits N3-adenine methylation by the compound, resulted in a threefold decrease in the toxicity. These results demonstrate the feasibility of this strategy for producing 3-MeA adducts in targeted cells.Copyright © 2011 Elsevier Ltd. All rights reserved.
Related Compounds
Related Articles:
2014-01-01
[Nucleic Acids Res. 42(17) , e130, (2014)]
2015-03-15
[Toxicol. Appl. Pharmacol. 283(3) , 187-97, (2015)]
2014-01-01
[PLoS ONE 9(6) , e99421, (2014)]
Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.
2014-01-01
[BMC Cancer 14 , 853, (2014)]
Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
2015-04-01
[Cancer Res. 75(7) , 1457-69, (2015)]